Body Vision Medical Signs Exclusive Agreement with Amco Corporation

6 June 2024

Body Vision Medical, a prominent company specializing in AI-powered intraoperative imaging devices, has recently inked an exclusive distribution agreement with AMCO Corporation.

This collaboration aims to introduce the state-of-the-art LungVision® real-time intraoperative CT imaging system to the Japanese market.

LungVision® harnesses the power of artificial intelligence (AI) to upgrade any C-arm fluoroscopy system into a sophisticated intraoperative imaging tool with advanced navigation capabilities.

This breakthrough technology enables bronchoscopists to conduct biopsies on small lung lesions with heightened speed and precision, thereby significantly enhancing early lung cancer detection and survival rates.

The significance of this partnership: "Japan boasts the highest lung cancer screening rate globally. Consequently, there's a substantial number of patients diagnosed with suspected lung nodules, underscoring the critical need for definitive diagnosis.

LungVision® offers the Japanese healthcare system a reliable and cost-effective solution for scaling up lung cancer screening efforts. This agreement with AMCO marks a pivotal milestone in granting Japanese clinicians and patients access to state-of-the-art lung cancer screening technology."